MediWound (NASDAQ:MDWD) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

MediWound Ltd. (NASDAQ:MDWD)’s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $17.12 and traded as high as $17.69. MediWound shares last traded at $17.35, with a volume of 27,770 shares traded.

Analyst Ratings Changes

Several analysts have recently weighed in on MDWD shares. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, MediWound has an average rating of “Hold” and a consensus price target of $31.67.

MediWound Stock Performance

The firm’s 50 day moving average price is $17.12 and its two-hundred day moving average price is $17.79. The company has a market cap of $222.95 million, a P/E ratio of -8.26 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. The company had revenue of $1.87 million during the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. As a group, analysts forecast that MediWound Ltd. will post -2.75 EPS for the current fiscal year.

Institutional Trading of MediWound

Several hedge funds have recently modified their holdings of the stock. Rhumbline Advisers increased its stake in MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 481 shares in the last quarter. Russell Investments Group Ltd. increased its stake in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. BNP Paribas Financial Markets increased its stake in MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares in the last quarter. Finally, Quarry LP bought a new stake in MediWound during the 4th quarter valued at $26,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.